WORKING TOWARD ZERO DEATHS BY 2030
We’re challenging all Bridge to 2030 teams to raise $10,000 for game-changing research. With your support, we can speed up the time it takes to make the next significant breast cancer breakthrough – and fast-track our progress towards zero deaths by 2030.
IMPACT OF YOUR FUNDRAISING
Could support a world-class research team to uncover how factors such as location, demographics and socio-economic conditions impact survival outcomes.
Could support a world-class research team to develop an innovative new blood test to more easily diagnose breast cancer & detect cancer relapse.
Could support a world-class research team to develop better predictive tests that detect the presence of resistant cancer cells well before they start to grow as secondary cancer.
WHAT FUNDING MEANS TO OUR RESEARCHER
We have a number of ground-breaking research projects focused on tackling the biggest hurdles to save lives from breast cancer. Here are two of our researchers… With your urgent support, we can fund more.
DR LIZ CALDON
Garvan Institute of Medical Research, NSW Project title: Discovering the mechanisms that cause anti-estrogen therapy resistance in breast cancer.
About 70% of all breast cancer types are estrogen receptor positive cancers that are treated with endocrine therapy. But a large number develop resistant to treatment and spread to other parts of the body. Metastatic recurrence in estrogen receptor-positive disease is the biggest contributor to mortality in breast cancer.
But NBCF-funded researcher Dr Liz Caldon is determined to change that. Her research is focused o
“NBCF has helped shape my research directed towards the discovery of mechanisms of drug resistance in breast cancer. They provided pivotal support at transition periods in my career when I have been establishing an independent research direction. The money you raise makes a big difference.”
PROFESSOR RICCARDO DOLCETTI
The University of Queensland, QLD Project title: Personalising immunotherapy for breast cancer.
A certain class of drugs that stimulate the immune system to attack cancer has shown promising results in previously untreatable cancers. However, at present, these drugs are only effective in a small number of breast cancers and may cause adverse immune reactions due to their lack of specificity. As such, there is a need to tailor a tumour fighting immune responses.
To overcome these limitations, NBCF-funded Professor Riccardo Dolcetti has developed a method to identify the unique antigens expressed by each individual breast cancer that can be targeted with personalised immunotherapy – using parts of one’s immune system to target cancer. Ultimately, his work hopes to lead to a clinical vaccine that boosts the immune system to target the hardest to treat forms of breast cancer.
“The funds you raise give highly motivated researchers more time, tools and resources to work on developing life-saving treatments for breast cancer patients.”